Lv2
120 积分 2025-10-17 加入
KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians
27天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
1个月前
已完结
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
1个月前
已完结
Immunotherapy Response and Survival Outcome by Immunophenotypic Signature in Non–Small Cell Lung Cancer
2个月前
已完结
Efficacy, safety, and exploratory biomarker analysis of rechallenge with immune checkpoint inhibitors combined with anlotinib in previously treated advanced non-small cell lung cancer
3个月前
已关闭
Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma
4个月前
已关闭
Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma
4个月前
已完结
BRCA and Breast Cancer-Related High-Penetrance Genes
4个月前
已完结
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
5个月前
已完结
皖公网安备34019202002308
